Pharma: Other News To Note
• Noven Pharmaceuticals Inc., of Miami, said it confirmed that it filed an abbreviated new drug application seeking approval to market its rivastigmine transdermal system in 4.6 mg/24 hours and 9.5 mg/24 hours dosage strengths.
